openPR Logo
Press release

SMi Group interviews SKAN AG's Richard Denk for the upcoming Highly Potent Active Pharmaceutical Ingredients conference in May.

03-04-2020 10:11 AM CET | Health & Medicine

Press release from: SMi Group

HPAPI

HPAPI

The 4th annual Highly Potent Active Pharmaceutical Ingredients conference will take place on the 11th - 12th May in London. The event will involve key profiles from leading pharma organisations to meet and discuss HPAPI manufacturing, where delegates will gain a better understanding of the oncology market and ADC production which is one of the main forces in the HPAPI industry.

The two-day conference will also explore the challenges in the industry, such as determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.

Ahead of the conference, SMi caught up with SKAN AG's Senior Consultant, Aseptic Processing & Containment Richard Denk, to review his insights on how the HPAPI market is developing, the importance of the 2020 conference, along with containment issues and challenges.

Snapshot of Richard's interview:

In your opinion, what are the current market drivers of the HPAPI industry?

"BioPharmaceuticals, Oral Solid Dosage Forms, API`s and the development of new novel medicines are one driver for the HPAPI Industry other drivers are regulatory requirements from the EMA. Since the exposure limits for use in risk identification in the EMA published the Guideline on setting health manufacture of different medicinal products in shared facilities, every product requires a PDE "Permitted Daily Exposure" and is calculated by experts. Beside Occupational Safety Requirements, GMP Requirements now also drive the expansion of Containment solutions".

As a containment expert, what would you say is the importance of a meeting on Highly Potent APIs? What major issues would you say are important to discuss in 2020?

"There are several important topics to cover in 2020. Within containment, for 20+ years we have been discussing protecting the operators from the hazardous substance. As a result, a lot of Containment Solutions and Transfer Systems are developed and many of them are successfully in use. Almost all of them have one common challenge that the operator has to get close to, the Containment connection of the hazardous substance. This could be for example on a flexible bag solution where the operator has to do some manipulation to make the Containment work. As one of the topics I`d like to highlight automation of containment for keeping the operator away from the hazardous substance..."

There will also be 2 interactive half-day post-conference workshop held by Justin Mason-Home, Director, HPAPI Project Services Limited, on the 13th of May to focus on "Practical Steps for Delivering HPAPI Projects." as well as David Embrey, Managing Director, Human Reliability Ltd. On "A roadmap to enhancing organisational safety in HPAPI manufacturing: A Human factors perspective".

For the full interview, speaker line-up and more information on the conference and registration, visit: http://www.highlypotentapi.com/openpr4

--- END ---

Highly Potent Active Pharmaceutical Ingredients
Main conference: 11th-12th May 2020
Post-conference workshop day: 13th May 2020
London, UK
Proudly sponsored by: BSP Pharmaceuticals
Exhibitor: Dec Group

To sponsor or exhibit at the conference, please contact Alia Malick on +44 (0) 207 827 6748 or amalick@smi-online.co.uk.

For all delegate enquiries, contact Dylan Brohm on +44 (0) 20 7827 1024 or dbrohm@smi-online.co.uk.

Ground Floor, India House, 45 Curlew Street

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release SMi Group interviews SKAN AG's Richard Denk for the upcoming Highly Potent Active Pharmaceutical Ingredients conference in May. here

News-ID: 1953797 • Views:

More Releases from SMi Group

Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug Discovery Conference
Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug D …
SMi Reports: Conference Chairman Darren Green from GSK personally invites you the 3rd Annual AI in Drug Discovery Conference taking place on 14th and 15th March 2022 in London, UK. The conference will have a focus on case studies from leading pharma and biotech firms, as well as a exploring the latest innovations in machine learning for enhancing discovery pipelines. Darren Green, Director of Computational Chemistry at GSK will be chairing at
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coast 2022
Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coa …
SMi Group reports: The 5th Annual Pharmaceutical Microbiology East Coast Conference is set to return in April 2022 with a key focus existing methods and novel tools in microbial control to assure continuity in product quality and patient safety. SMi Group is delighted to announce the 5th Annual Pharmaceutical Microbiology East Coast Conference, taking place on the 27th and 28th April 2022 in Boston, USA. The 2022 Conference theme is
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Conference with Online Access Only
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Confer …
SMi Reports: SMi Group have made the decision to open the microbiology conference and workshops to all microbiologists by transforming it into a virtual-remote online access event only on 17th and 18th January 2022. SMi’s 10th Annual Pharmaceutical Microbiology UK Conference will no longer take place in London, UK. Instead, the conference is taking place on 17 and 18 January 2022 and will open its doors to a global audience delivering
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th Annual 3D Cell Culture Conference
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th A …
SMi Group reports: Co-Chairs, Philip Hewitt and Stefan Pryzyborski for SMi’s 5th Annual 3D Cell Culture invite industry professionals to join the conference in February 2022. Philip Hewitt, Global Head of Early Investigative Toxicology, Merck and Stefan Przyborski, Professor in Cell Technology, Durham University invite industry professionals by releasing invite letter to join SMi’s 5th Annual 3D Cell Culture Conference 2022. This event will convene on February 9th – 10th 2022,

All 5 Releases


More Releases for HPAPI

HPAPI Market: Opportunities and Challenges
The global HPAPIs Market is projected to register a CAGR of 8.7% during the forecast period (2018-23). The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies and growing focus on precision medicine. However, factors such as the requirement of large investments, discrepancies in HPAPI banding
New Technologies for HPAPI Manufacturing and Containment
SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production. At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures. Key highlights include: Alternative HPAPI manufacturing technologies to
The Latest Innovations in HPAPI Manufacturing Technologies
SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements. Keith Jensen, Owner and Consultant at Keith Jensen Consulting, previously at Novartis-MIT Center for Continuous Manufacturing, discusses alternative HPAPI manufacturing technologies to reduce powder exposure and improve safety enabling continuous manufacturing. Other
HPAPI 2019 Conference: Exclusive Interview Released with AstraZeneca
Peter Marshall from AstraZeneca will be speaking at SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference which will take place in London on 13th-14th May. He will be discussing the latest developments in the industry with a specific focus on the principles of pharmaceutical containment in isolator design. Ahead of the conference, SMi had interviewed him where he gave a taster of what he will be discussing. Peter said: “The
The Latest Techniques in HPAPI Facility Design
Amongst the myriad of potential pitfalls for the Highly Potential Active Pharmaceutical Ingredients (HPAPI) industry there is a requirement for all parties involved to have a blueprint in place to ensure all containment procedures are followed correctly. Yet, there is also a need to ensure that operations are maintained at the highest standards. At SMi’s 3rd Annual Highly Potent Active Pharmaceutical Ingredients Conference these issues will be discussed along with
HPAPI (High Potency Active Pharmaceutical Ingredients) Market Report 2018: Segme …
Global HPAPI (High Potency Active Pharmaceutical Ingredients) market research report provides company profile for Lonza, Novasep, Thermofisher Scientific, Alkermes, Cambrex, Dishman, Dr. Reddy’S and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report